RxDoctor Payments Data

Simone Rubin, DO

Adult Medicine · Rochelle Park, NJNPI 1710545959

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Intra-sana Laboratories at 25.1% of the total.

$499in general payments, 2019–2025

Across 16 payments — averaging $31.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intra-sana Laboratories$125
  • AstraZeneca$125
  • Exact Sciences$72
  • Lilly USA, LLC$51
  • Boehringer Ingelheim$51
  • Dynavax Technologies Corporation$31
  • plus $43 from 2 others

What the payments were for

  • Food & beverage$499100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$499 in reported general payments places this provider in the 55th percentile of 48 adult medicine providers in New Jersey.

See all adult medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$97,316
Medicare patients
228
Services billed
1,506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide74$88,021
OzempicSemaglutide34$64,185
FarxigaDapagliflozin Propanediol21$21,691
EliquisApixaban18$14,566
WegovySemaglutide11$14,195
JardianceEmpagliflozin11$13,984
InvokanaCanagliflozin16$13,306
Repatha SureclickEvolocumab13$7,031
Rosuvastatin Calcium185$2,707
SymbicortBudesonide/Formoterol Fumarate12$2,693
Atorvastatin Calcium239$2,162
SynthroidLevothyroxine Sodium31$2,038
Duloxetine Hcl69$1,670
Amlodipine Besylate182$1,474
Escitalopram Oxalate75$1,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$51$88,02174 claims
Novo NordiskOzempic, Wegovy$29$78,38045 claims
AstraZenecaFarxiga, Symbicort$125$24,38533 claims
PfizerEliquis$15$14,56618 claims
Boehringer IngelheimJardiance$51$13,98411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 48 adult medicine providers in New Jersey.

Other adult medicine in Rochelle Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →